Skip to Main Content

Results released Monday from a Phase 2 study of a chronic cough treatment being developed by Bellus Health exceeded the expectations of financial analysts and boost the company’s chances of eventual approval after an earlier trial of the drug had failed.

Bellus said in a press release it expects to meet with the Food and Drug Administration in the second quarter of 2022 and to begin a Phase 3 study of the treatment in the second half of 2022. Roberto Bellini, Bellus’ CEO, said the company is “extremely pleased” with the “compelling” results.


Results with the lowest 12-milligram dose of the treatment, BLU-5937, were not statistically significant. But results for the 50-milligram and 200-milligram doses were significant, reducing the frequency of coughs by 34.4% and 34.2%, respectively.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.